Boehringer Ingelheim has announced the call for proposals for the 2026 Advancement in Equine Research Awards.
“Boehringer is committed to collaborating with the community of researchers, veterinarians, and diagnosticians who dedicate their time and energy to improving the lives of horses through research,” says Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer. “The Equine Research Awards program has been invaluable in advancing what we know about infectious disease.”
Public and private researchers in the United States, Canada, and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment and understanding of equine infectious disease. Boehringer will present five separate $15,000 awards.
Proposals must be submitted by Sept. 15, 2026, and will be reviewed by an independent board consisting of renowned equine industry professionals, including practicing veterinarians and researchers. The board will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality, and scientific quality. The award recipients will be announced at the 72nd annual American Association of Equine Practitioners Convention in Las Vegas, Nevada, which will take place from Dec. 7-11, 2026.
Again this year, Boehringer will accept electronic copies of the proposals in lieu of hard copies. To participate in the 2026 awards program, submit an e-copy proposal, cover letter, and Curriculum Vitae to Dr. Joe Lyman at joseph.lyman@boehringer-ingelheim.com.
The Boehringer Advancement in Equine Research Awards program was launched in 2011 to support veterinary research that results in practical applications for insights into important equine infectious and non-infectious diseases. Nearly $1 million has been awarded to date for emerging science in equine research.
For more information and complete submission instructions, please visit: https://bi-animalhealth.com/equine/initiatives/equine-research-awards/instructions.
About Boehringer Ingelheim – Animal Health business
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/us/animal-health.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Stay in the know! Sign up for EquiManagement’s FREE weekly newsletters to get the latest equine research, disease alerts, and vet practice updates delivered straight to your inbox.
